Cover Image

Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes

Saved in:

Bibliographic Details
Main Authors:	LiGang Huang (Author), Rong Hu (Author), HaiTao Zou (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
by: Dao-Gen Yin, et al.
Published: (2021)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024)

Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role?
by: Asmaa Elrakaybi, et al.
Published: (2022)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model
by: Oleg eDemin Jr, et al.
Published: (2014)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
by: Li-Min Zhao, et al.
Published: (2022)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
by: Shiwen Yang, et al.
Published: (2023)

The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022)

SGLT2 Inhibitors and Fracture Risk in Elderly Population
by: Vishal R Tandon, et al.
Published: (2023)

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
by: Melpomeni Peppa, et al.
Published: (2023)

SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety
by: Klaudia Kułak, et al.
Published: (2024)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023)

SGLT1: A Potential Drug Target for Cardiovascular Disease
by: Zhao M, et al.
Published: (2023)

SGLT2-Inhibitors - significant role in Heart Failure treatment
by: Karol Wielgus, et al.
Published: (2024)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
by: Pasquale Paolisso, et al.
Published: (2023)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
by: Maria Elena Lunati, et al.
Published: (2022)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024)

Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns
by: Farazul Hoda, et al.
Published: (2024)

Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence
by: Junhao Lv, et al.
Published: (2023)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
by: Lingxiang Xie, et al.
Published: (2022)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
by: Lea El Hage MD, et al.
Published: (2019)

SGLT-2 inhibitors: new effective drugs for treatment of heart failure
by: Olgierd Król, et al.
Published: (2022)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
by: Nauck MA
Published: (2014)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
by: Aurélie Pahud de Mortanges, et al.
Published: (2021)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024)

Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world
by: Rongjing Song, et al.
Published: (2024)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports
by: Joanna Winciorek, et al.
Published: (2024)

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
by: Li N, et al.
Published: (2020)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

SGLT-2 Inhibitors in Kidney Transplant Recipients: Our Story So Far
by: Luís Leite de Sousa, et al.
Published: (2023)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
by: Xiang Zhou, et al.
Published: (2021)